THRD Key Statistics, Chart & Performance
The current stock price of THRD is 5.38 USD. In the past month the price decreased by -0.55%. In the past year, price decreased by -51.58%.
THRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About THRD
Company Profile
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
Company Info
Third Harmonic Bio Inc
1700 Montgomery Street, Suite 210
San Francisco CALIFORNIA US
Employees: 42
Phone: 12097272457
Third Harmonic Bio Inc / THRD FAQ
What does THRD do?
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
What is the current price of THRD stock?
The current stock price of THRD is 5.38 USD. The price decreased by -0.09% in the last trading session.
What is the dividend status of Third Harmonic Bio Inc?
THRD does not pay a dividend.
What is the ChartMill technical and fundamental rating of THRD stock?
THRD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting THRD stock to perform?
6 analysts have analysed THRD and the average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.
What is the market capitalization of THRD stock?
Third Harmonic Bio Inc (THRD) has a market capitalization of 242.80M USD. This makes THRD a Micro Cap stock.
THRD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to THRD. When comparing the yearly performance of all stocks, THRD is a bad performer in the overall market: 90.71% of all stocks are doing better.
THRD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRD. No worries on liquidiy or solvency for THRD as it has an excellent financial health rating, but there are worries on the profitability.
THRD Financial Highlights
Over the last trailing twelve months THRD reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -89.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.1% | ||
| ROE | -19.6% | ||
| Debt/Equity | 0 |
THRD Forecast & Estimates
6 analysts have analysed THRD and the average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.